Elacestrant Improves PFS in ESR1-Mutant Metastatic Breast Cancer Subgroups
Treatment with elacestrant led to a clinically meaningful improvement in progression-free-survival compared with standard-of-care therapy among patients with estrogen receptor–positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
San Antonio United States Janice Lu Northwestern University Lurie Comprehensive Cancer Center Antonio Breast Cancer Bidardf C
Source: onclive.com